Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Inclusion Criteria:

- Age ≥18 years.

- Has pancreatic ductal adenocarcinoma

- Has resectable disease at the time of diagnosis

- Has not received any systemic therapy for pancreatic ductal adenocarcinoma

- Has stage ≤ IIb disease at time of diagnosis and enrollment

- Elevated tumor marker, CA (carbohydrate antigen) 19-9 >200

- ECOG performance status 0 or 1

- Patient must have adequate organ function defined by the study-specified laboratory
tests.

- Must use acceptable form of birth control while on study.

- Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

Patients who have received any prior chemotherapy, radiotherapy or investigational agents
for pancreatic cancer.

- Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2,
anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell
receptor (e.g., CTLA-4, OX 40, CD137).

- Has received prior therapy with FAK inhibitor.

- Woman who are pregnant or breastfeeding.

- Have received a live vaccine within 30 days prior to study drug.

- Is currently or has participated in another investigational study within 4 weeks prior
to receiving study drug.

- History or current use of immunosuppressive medications within 7 days prior to study
medications.

- Has a known additional malignancy that is progressing or has required active treatment
within the past 2 years or that is expected to require active treatment within two
years.

- Has active autoimmune disease that has required systemic treatment in the past 2
years.

- Has a history of (non-infectious) pneumonitis or current pneumonitis.

- Has an active infection requiring systemic therapy.

- Infection with HIV or hepatitis B or C.

- Patient with uncontrolled intercurrent illness including, but not limited to,
uncontrolled infection, symptomatic congestive heart failure, unstable angina
pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
limit compliance with study requirements.

- Known allergy or hypersensitivity to the study drugs.

- Received any growth factors including, but not limited to, granulocyte-colony
stimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of study drug
administration.

- Has history of any organ transplant, including corneal transplants.